SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Pilatus Biosciences Presents Preclinical PLT012 Data at SITC 2026

The company presented preclinical data on PLT012's potential to overcome immunotherapy resistance in liver cancer. Research identifies CD36-mediated lipid metabolism as a driver of acquired resistance to PD-1 immunotherapy.

Related stories